By the WoundSource Editors
Mississauga, ON – March 7, 2017 – NOVADAQ recently announced that Cigna has reviewed the growing base of evidentiary support and now covers DermACELL when used in association with a covered medically necessary breast reconstruction procedure. DermACELL AWM® has also been approved for coverage as medically necessary for diabetic foot ulcers when the following criteria are met: partial- or full-thickness diabetic foot ulcers of greater than four weeks duration for which standard wound therapy has failed; the treated foot has adequate blood supply as evidenced by either the presence of a palpable pedal pulse or an ankle-brachial index (ABI) of ≥ 0.70. Now more than 15 million Cigna members throughout 30 states including Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland, Missouri, North and South Carolina, Tennessee, Texas and Virginia will have coverage for DermACELL and DermACELL AWM. Cigna joins several other payers who cover DermACELL including Medicare and UnitedHealthCare.